Kalaris Therapeutics, Inc. (KLRS) stock
KLRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.37−0.06 (-4.20%)
Close on Nov 18, 2026Market cap $32.61MP/E –Yield –
Kalaris Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Kalaris Therapeutics's revenue for the twelve months ending Dec 31, 2019 was $165.00K. For fiscal 2019 it was $165.00K.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $165.00K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2019 | Dec 31, 2019 | $0 | – |
| Q3 FY2019 | Sep 30, 2019 | $0 | – |
See a number that looks wrong?